Pulmonary hypertension in chronic obstructive pulmonary disease

European Respiratory Journal

Volumn 21, Issue 5, 2003, Pages 892-905

  Barbera J A ^a   Peinado, V I ^a   Santos, S ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Chronic hypoxaemia; Cigarette smoke effects; Endothelium; Pulmonary artery; Vascular remodelling; Vasodilators

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BOSENTAN; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; CIGARETTE SMOKE; DIGITALIS; ENDOTHELIN A RECEPTOR ANTAGONIST; FUROSEMIDE; LOOP DIURETIC AGENT; NIFEDIPINE; NITRIC OXIDE; OXYGEN; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN DERIVATIVE; SILDENAFIL; THEOPHYLLINE; VASODILATOR AGENT;

BLOOD VESSEL TONE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIGITALIS INTOXICATION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; EXERCISE; HEART OUTPUT; HEART RIGHT VENTRICLE FUNCTION; HUMAN; HYPOKALEMIA; LONG TERM CARE; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG CIRCULATION; LUNG ENDOTHELIUM; LUNG FUNCTION; LUNG GAS EXCHANGE; LUNG SURGERY; METABOLIC ALKALOSIS; OXYGEN THERAPY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; SLEEP; SMOKING; SURVIVAL TIME;

ANOXEMIA; HUMANS; HYPERTENSION, PULMONARY; LUNG; PULMONARY ARTERY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY MUCOSA; SMOKING;

EID: 0038056173     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00115402     Document Type: Review

References (132)

1. Fishman AP. State of the art: chronic cor pulmonale. Am Rev Respir Dis 1976; 114: 775-794.
2. Weitzenblum E, Kessler R, Oswald M, Fraisse Ph. Medical treatment of pulmonary hypertension in chronic lung disease. Eur Respir J 1994; 7: 148-152.
3. Pietra GG. Pathology of the pulmonary vasculature and heart. In: Cherniack NS, ed. Chronic obstructive pulmonary disease. Philadelphia, W.B. Saunders, 1991; pp. 21-26.
4. Burrows B, Kettel LJ, Niden AH, Rabinowitz M, Diener CF. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med 1972; 286: 912-918.
5. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981; 36: 752-758.
6. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Hirth C, Roegel E. Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 130: 993-998.
7. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002; 166: 314-322.
8. Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study. Am Rev Respir Dis 1979; 119: 895-902.
9. Oswald-Mammosser M, Weitzenblum E, Quoix E, et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995; 107: 1193-1198.
10. Burgess MI, Mogulkoc N, Bright-Thomas RJ, Bishop P, Egan JJ, Ray SG. Comparison of echocardiographic markers of right ventricular function in determining prognosis in chronic pulmonary disease. J Am Soc Echocardiogr 2002; 15: 633-639.
11. Incalzi RA, Fuso L, De Rosa M, et al. Electrocardiographic signs of chronic cor pulmonale: A negative prognostic finding in chronic obstructive pulmonary disease. Circulation 1999; 99: 1600-1605.
12. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors or hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 158-164.
13. Kessler R, Faller M, Weitzenblum E, et al. "Natural history" of Pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164: 219-224.
14. Barberà JA, Riverola A, Roca J, et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 149: 423-429.
15. Peinado VI, Barberà JA, Ramirez J, et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol 1998; 274: L908-L913.
16. Wright JL, Petty T, Thurlbeck WM. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung 1992; 170: 109-124.
17. Wilkinson M, Langhorne CA, Heath D, Barer GR, Howard P. A pathophysiological study of 10 cases of hypoxic cor pulmonale. Q J Med 1988; 249: 65-85.
18. Magee F, Wright JL, Wiggs BR, Paré PD, Hogg JC. Pulmonary vascular structure and function in chronic obstructive pulmonary disease. Thorax 1988; 43: 183-189.
19. Wright JL, Lawson L, Paré PD, et al. The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease. Am Rev Respir Dis 1983; 128: 702-707.
20. Hale KA, Niewoehner DE, Cosio MG. Morphologic changes in the muscular pulmonary arteries: Relationship to cigarette smoking, airway disease, and emphysema. Am Rev Respir Dis 1980; 122: 273-278.
21. Santos S, Peinado VI, Ramirez J, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002; 19: 632-638.
22. Dinh-Xuan AT, Higenbottam T, Clelland C, et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive pulmonary disease. N Engl J Med 1991; 324: 1539-1547.
23. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-221.
24. Barberà JA, Peinado VI, Santos S, Ramirez J, Roca J, Rodriguez-Roisin R. Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers. Am J Respir Crit Care Med 2001; 164: 709-713.
25. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-1932.
26. Wedgwood S, Dettman RW, Black SM. ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am J Physiol 2001; 281: L1058-L1067.
27. Giaid A, Yanagisawa M, Langblen D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.
28. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 1995; 95: 1798-1807.
29. Santos S, Peinado VI, Barberà JA, Ramirez J, Roca J, Gimferrer JM, Rodriguez-Roisin R. Enhanced expression of vascular endothelial growth factor (VEGF) in pulmonary muscular arteries of patients with COPD. Eur Respir J 2000; 16: Suppl. 31, 86s.
30. Heath D, Smith P, Rios DJ, Williams D, Harris P. Small pulmonary arteries in some natives of La Paz, Bolivia. Thorax 1981; 36: 599-604.
31. Meyrick B, Reid L. The effect of continued hypoxia on rat pulmonary arterial circulation. An ultrastructural study. Lab Invest 1978; 38: 188-200.
32. Stenmark K, Durmowicz AG, Dempsey EC. Modulation of vascular wall cell phenotype in pulmonary hypertension. In: Bishop JE, Reeves JT, Laurent GJ, eds. Pulmonary vascular remodelling. London, Portland Press, 1995; pp. 171-212.
33. Weitzenblum E, Schrijen F, Mohan-Kumar T, Colas dFV, Lockhart A. Variability of the pulmonary vascular response to acute hypoxia in chronic bronchitis. Chest 1988; 94: 772-778.
34. Ashutosh K, Mead G, Dunsky M. Early effects of oxygen administration and prognosis in chronic obstructive pulmonary disease and cor pulmonale. Am Rev Respir Dis 1983; 127: 399-404.
35. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 131: 493-498.
36. Peinado VI, Barberà JA, Abate P, et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1605-1611.
37. Wright JL, Churg A. Effect of long-term cigarette smoke exposure on pulmonary vascular structure and function in the guinea pig. Exp Lung Res 1991; 17: 997-1009.
38. Voelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995; 8: 2129-2138.
39. Su Y, Han W, Giraldo C, Li YD, Block ER. Effect of cigarette smoke extract on nitric oxide synthase in pulmonary artery endothelial cells. Am J Respir Cell Mol Biol 1998; 19: 819-825.
40. Yamato H, Churg A, Wright JL. Guinea pig pulmonary hypertension caused by cigarette smoke cannot be explained by capillary bed destruction. J Appl Physiol 1997; 82: 1644-1653.
41. Peinado VI, Santos S, Ramirez J, Roca J, Rodriguez-Roisin R, Barberà JA. Response to hypoxia of pulmonary arteries in COPD: an in vitro study. Eur Respir J 2002; 20: 332-338.
42. Naeije R. Should pulmonary hypertension be treated in chronic obstructive pulmonary disease?. In: Weir EK, Archer SL, Reeves JT, eds. The diagnosis and treatment of pulmonary hypertension. Mount Kisco, Futura Publishing, 1992; pp. 209-239.
43. Stevens D, Sharma K, Szidon P, Rich S, McLaughlin V, Kesten S. Severe pulmonary hypertension associated with COPD. Ann Transplant 2000; 5: 8-12.
44. Barberà JA. Chronic obstructive pulmonary disease. In: Roca J, Rodriguez-Roisin R, Wagner PD, eds. Pulmonary and peripheral gas exchange in health and disease. New York, Marcel Dekker, Inc., 2000; pp. 229-261.
45. Roca J, Wagner PD. Contribution of multiple inert gas elimination technique to pulmonary medicine. 1. Principles and information content of the multiple inert gas elimination technique. Thorax 1994; 49: 815-824.
46. Barberà JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996; 347: 436-440.
47. Mélot C, Hallemans R, Naeije R, Mols P, Lejeune P. Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 130: 612-616.
48. Ringsted CV, Eliasen K, Andersen JB, Heslet L, Qvist J. Ventilation-perfusion distributions and central hemodynamics in chronic obstructive pulmonary disease. Effects of terbutaline administration. Chest 1989; 96: 976-983.
49. Agustí AGN, Barberà JA, Roca J, Wagner PD, Guitart R, Rodriguez-Roisin R. Hypoxic pulmonary vasoconstriction and gas exchange during exercise in chronic obstructive pulmonary disease. Chest 1990; 97: 268-275.
50. Simonneau G, Escourrou P, Duroux P, Lockhart A. Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. N Engl J Med 1981; 304: 1582-1585.
51. MacNee W, Wathen CG, Hannan WJ, Flenley DC, Muir AL. Effects of pirbuterol and sodium nitroprusside on pulmonary haemodynamics in hypoxic cor pulmonale. BMJ (Clin Res Ed) 1983; 287: 1169-1172.
52. Lee-Chiong TL, Matthay RA. The heart in the stable COPD patient. In: Similowski T, Whitelaw WA, Derenne JP, eds. Clinical management of chronic obstructive pulmonary disease. New York, Marcel Dekker, Inc., 2002; pp. 475-532.
53. Brent BN, Berger HJ, Matthay RA, Mahler D, Pytlik L, Zaret BL. Physiologic correlates of right ventricular ejection fraction in chronic obstructive pulmonary disease: a combined radionuclide and hemodynamic study. Am J Cardiol 1982; 50: 255-262.
54. Weitzenblum E, Chaouat A. Right ventricular function in COPD: can it be assessed reliably by the measurement of right ventricular ejection fraction? Chest 1998; 113: 567-569.
55. Crottogini AJ, Willshaw P. Calculating the end-systolic pressure-volume relation. Circulation 1991; 83: 1121-1123.
56. Biernacki W, Flenley DC, Muir AL, MacNee W. Pulmonary hypertension and right ventricular function in patients with COPD. Chest 1988; 94: 1169-1175.
57. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. Am J Respir Crit Care Med 1994; 150: 833-852.
58. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part Two. Am J Respir Crit Care Med 1994; 150: 1158-1168.
59. Barberà JA, Roca J, Ferrer A, et al. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 1285-1291.
60. Weitzenblum E, Apprill M, Oswald M, Chaouat A, Imbs JL. Pulmonary hemodynamics in patients with chronic obstructive pulmonary disease before and during an episode of peripheral edema. Chest 1994; 105: 1377-1382.
61. Campbell EJM, Short DS. The cause of oedema in "cor pulmonale". Lancet 1960; I: 1184-1186.
62. Baudouin SV. Oedema and cor pulmonale revisited. Thorax 1997; 52: 401-402.
63. MacNee W, Wathen CG, Flenley DC, Muir AD. The effects of controlled oxygen therapy on ventricular function in patients with stable and decompensated cor pulmonale. Am Rev Respir Dis 1988; 137: 1289-1295.
64. Palange P. Renal and hormonal abnormalities in chronic obstructive pulmonary disease (COPD). Thorax 1998; 53: 989-991.
65. Harris P, Segal N, Bishop JM. The relation between pressure and flow in the pulmonary circulation in normal subjects and in chronic bronchitis. Cardiovasc Res 1968; 2: 73-83.
66. Naeije R, Barberà JA. Pulmonary hypertension associated with COPD. Crit Care 2001; 5: 286-289.
67. Butler J, Schrijen F, Henriquez A, Polu JM, Albert RK. Cause of the raised wedge pressure on exercise in chronic obstructive Pulmonary disease. Am Rev Respir Dis 1988; 138: 350-354.
68. Montes de Oca M, Rassulo J, Celli BR. Respiratory muscle and cardiopulmonary function during exercise in very severe COPD. Am J Respir Crit Care Med 1996; 154: 1284-1289.
69. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986; 250: H1145-H1149.
70. Roger N, Barberà JA, Roca J, Rovira I, Gomez FP, Rodriguez-Roisin R. Nitric oxide inhalation during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 800-806.
71. Weitzenblum E. The pulmonary circulation and the heart in chronic lung disease. Monaldi Arch Chest Dis 1994; 49: 231-234.
72. Chetty KG, Brown SE, Light RW. Identification of pulmonary hypertension in chronic obstructive pulmonary disease from routine chest radiographs. Am Rev Respir Dis 1982; 126: 338-341.
73. Wiedemann HP, Matthay RA. Heart Disease. A Textbook of Cardiovascular Medicine. 5th Edn. Philadelphia, WB Saunders Company, 1997.
74. Oswald-Mammosser M, Oswald T, Nyankiye E, Dickele MC, Grange D, Weitzenblum E. Non-invasive diagnosis of pulmonary hypertension in chronic obstructive pulmonary disease. Comparison of ECG, radiological measurements, echocardiography and myocardial scintigraphy. Eur J Respir Dis 1987; 71: 419-429.
75. Torbicki A, Skwarski K, Hawrylkiewicz I, Pasierski T, Miskiewicz Z, Zielinski J. Attempts at measuring pulmonary arterial pressure by means of Doppler echocardiography in patients with chronic lung disease. Eur Respir J 1989; 2: 856-860.
76. Laaban JP, Diebold B, Zelinski R, Lafay M, Raffoul H, Rochemaure J. Noninvasive estimation of systolic pulmonary artery pressure using Doppler echocardiography in patients with chronic obstructive pulmonary disease. Chest 1989; 96: 1258-1262.
77. Naeije R, Torbicki A. More on the noninvasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. Eur Respir J 1995; 8: 1445-1449.
78. Takakura M, Harada T, Fukuno H, et al. Echocardiographic detection of occult cor pulmonale during exercise in patients with chronic obstructive pulmonary disease. Echocardiography 1999; 16: 127-134.
79. Matsuyama W, Ohkubo R, Michizono K, et al. Usefulness of transcutaneous Doppler jugular venous echo to predict pulmonary hypertension in COPD patients. Eur Respir J 2001; 17: 1128-1131.
80. Kruger S, Haage P, Hoffmann R, et al. Diagnosis of pulmonary arterial hypertension and pulmonary embolism with magnetic resonance angiography. Chest 2001; 120: 1556-1561.
81. Agustí AGN, Cotes J, Wagner PD. Responses to exercise in lung diseases. Eur Respir Mon 1997; 6: 32-50.
82. Minh VD, Lee HM, Dolan GF, Light RW, Bell J, Vasquez P. Hypoxemia during exercise in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1979; 120: 787-794.
83. Nery LE, Wasserman K, French W, Oren A, Davis JA. Contrasting cardiovascular and respiratory responses to exercise in mitral valve and chronic obstructive pulmonary diseases. Chest 1983; 83: 446-453.
84. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161: 487-492.
85. Troosters T, Vilaro J, Rabinovich R, et al. Physiological responses to the 6-min walk test in patients with chronic obstructive pulmonary disease. Eur Respir J 2002; 20: 564-569.
86. Celli BR, Cote CG, Marín JM, Montes de Oca M, Casanova C, Méndez R. Combining 6MWD, FEV1, MRC dyspnea and BMI is better predictor of mortality than FEV1. Am J Respir Crit Care Med 2001; 163: A504.
87. Gerardi DA, Lovett L, Benoit-Connors ML, Reardon JZ, ZuWallack RL. Variables related to increased mortality following out-patient pulmonary rehabilitation. Eur Respir J 1996; 9: 431-435.
88. Troosters T, Gosselink R, Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Am J Med 2000; 109: 207-212.
89. Galie N, Manes A, Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur Respir J 2002; 20: 1037-1049.
90. Kharitonov SA, Barnes PJ. Exhaled Markers of Pulmonary Disease. Am J Respir Crit Care Med 2001; 163: 1693-1722.
91. Kharitonov SA, Cailes JB, Black CM, du Bois RM, Barnes PJ. Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension. Thorax 1997; 52: 1051-1055.
92. Riley MS, Porszasz J, Miranda J, Engelen MP, Brundage B, Wasserman K. Exhaled nitric oxide during exercise in primary pulmonary hypertension and pulmonary fibrosis. Chest 1997; 111: 44-50.
93. Clini E, Cremona G, Campana M, et al. Production of endogenous nitric oxide in chronic obstructive pulmonary disease and patients with cor pulmonale. Correlates with echo-Doppler assessment. Am J Respir Crit Care Med 2000; 162: 446-450.
94. Yusen RD, Lefrak SS, Trulock EP. Evaluation and preoperative management of lung volume reduction surgery candidates. Clin Chest Med 1997; 18: 199-224.
95. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
96. Muramoto A, Caldwell J, Albert RK, Lakshminarayan S, Butler J. Nifedipine dilates the pulmonary vasculature without producing symptomatic systemic hypotension in upright resting and exercising patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 132: 963-966.
97. Naeije R, Melot C, Mols P, Hallemans R. Effects of vasodilators on hypoxic pulmonary vasoconstriction in normal man. Chest 1982; 82: 404-410.
98. Bratel T, Hedenstierna G, Nyquist O, Ripe E. The use of a vasodilator, felodipine, as an adjuvant to long-term oxygen treatment in COLD patients. Eur Respir J 1990; 3: 46-54.
99. Andrivet P, Chabrier PE, Defouilloy C, Brun-Buisson C, Adnot S. Intravenously administered atria] natriuretic factor in patients with COPD. Effects on ventilation-perfusion relationships and pulmonary hemodynamics. Chest 1994; 106: 118-124.
100. Adnot S, Kouyoumdjian C, Defouilloy C, et al. Hemodynamic and gas exchange responses to infusion of acetylcholine and inhalation of nitric oxide in patients with chronic obstructive lung disease and pulmonary hypertension. Am Rev Respir Dis 1993; 148: 310-316.
101. Sturani C, Bassein L, Schiavina M, Gunella G. Oral nifedipine in chronic cor pulmonale secondary to severe chronic obstructive pulmonary disease (COPD). Chest 1983; 84: 135-142.
102. Agostoni P, Doria E, Galli C, Tamborini G, Guazzi MD. Nifedipine reduces pulmonary pressure and vascular tone during short- but not long-term treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 139: 120-125.
103. Saadjian AY, Philip-Joet FF, Vestri R, Arnaud AG. Long-term treatment of chronic obstructive lung, disease by Nifedipine: an 18-month haemodynamic study. Eur Respir J 1988; 1: 716-720.
104. Pauwels RA, Buist AS, Calverley PMA, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
105. Katayama Y, Higenbottam TW, Diaz de Atauri MJ, et al. Inhaled nitric oxide and arterial oxygen tension in patients with chronic obstructive pulmonary disease and severe pulmonary hypertension. Thorax 1997; 52: 120-124.
106. Frostell C, Blomqvist H, Hedenstierna G, Lundberg J, Zapol WM. Inhaled nitric oxide selectively reverses human hypoxic pulmonary vasoconstriction without causing systemic vasodilation. Anesthesiology 1993; 78: 427-435.
107. Katayama Y, Higenbottam TW, Cremona G, et al. Minimizing the inhaled dose of NO with breath-by-breath delivery of spikes of concentrated gas. Circulation 1998; 98: 2429-2432.
108. Siddons TE, Asif M, Higenbottam T. Does the method of delivery of inhaled nitric oxide influence oxygenation and VA/Q patterns in severe COPD? Eur Respir J 2000; 16: Suppl. 31, 267s.
109. Yoshida M, Taguchi O, Gabazza EC, et al. Combined inhalation of nitric oxide and oxygen in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 155: 526-529.
110. Germann P, Ziesche R, Leitner C, et al. Addition of nitric oxide to oxygen improves cardiopulmonary function in patients with severe COPD. Chest 1998; 114: 29-35.
111. Ashutosh K, Phadke K, Jackson JF, Steele D. Use of nitric oxide inhalation in chronic obstructive pulmonary disease. Thorax 2000; 55: 109-113.
112. DeGaute JP, Domenighetti G, Naeije R, Vincent JL, Treyvaud D, Perret C. Oxygen delivery in acute exacerbation of chronic obstructive pulmonary disease. Effects of controlled oxygen therapy. Am Rev Respir Dis 1981; 124: 26-30.
113. Lejeune P, Mols P, Naeije R, Hallemans R, Melot C. Acute hemodynamic effects of controlled oxygen therapy in decompensated chronic obstructive pulmonary disease. Crit Care Med 1984; 12: 1032-1035.
114. Olvey SK, Reduto LA, Stevens PM, Deaton WJ, Miller RR. First pass radionuclide assessment of right and left ventricular ejection fraction in chronic pulmonary disease. Effect of oxygen upon exercise response. Chest 1980; 78: 4-9.
115. Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; i: 681-685.
116. Nocturnal oxygen therapy trial group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. A clinical trial. Ann Intern Med 1980; 93: 391-398.
117. Brijker F, Heijdra YF, van den Elshout FJ, Folgering HT. Discontinuation of furosemide decreases PaCO2 in patients with COPD. Chest 2002; 121: 377-382.
118. Mathur PN, Powles P, Pugsley SO, McEwan MP, Campbell EJ. Effect of digoxin on right ventricular function in severe chronic airflow obstruction. A controlled clinical trial. Ann Intern Med 1981; 95: 283-288.
119. Polic S, Rumboldt Z, Dujic Z, Bagatin J, Deletis O, Rozga A. Role of digoxin in right ventricular failure due to chronic cor pulmonale. Int J Clin Pharmacol Res 1990; 10: 153-162.
120. Matthay RA, Berger HJ, Loke J, Gottschalk A, Zaret BL. Effects of aminophylline upon right and left ventricular performance in chronic obstructive pulmonary disease: noninvasive assessment by radionuclide angiocardiography. Am J Med 1978; 65: 903-910.
121. Mols P, Ham H, Naeije N, et al. How does salbutamol improve the ventricular performance in patients with chronic obstructive pulmonary disease? J Cardiovasc Pharmacol 1988; 12: 127-133.
122. Ballester E, Roca J, Ramis L, Wagner PD, Rodriguez-Roisin R. Pulmonary gas exchange in severe chronic asthma. Response to 100%, oxygen and salbutamol. Am Rev Respir Dis 1990; 141: 558-562.
123. Chetty KG, Brown SE, Light RW. Improved exercise tolerance of the polycythemic lung patient following phlebotomy. Am J Med 1983; 74: 415-420.
124. Borst MM, Leschke M, Konig U, Worth H. Repetitive hemodilution in chronic obstructive pulmonary disease and pulmonary hypertension: effects on pulmonary hemodynamics, gas exchange, and exercise capacity. Respiration 1999; 66: 225-232.
125. Cooper JD, Patterson GA, Sundaresan RS, et al. Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema. J Thorac Cardiovasc Surg 1996; 112: 1319-1329.
126. Weg IL, Rossoff L, McKeon K, Michael GL, Scharf SM. Development of pulmonary hypertension after lung volume reduction surgery. Am J Respir Crit Care Med 1999; 159: 552-556.
127. Sciurba FC, Rogers RM, Keenan RJ, et al. Brown ML, Landreneau RJ. Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema. N Engl J Med 1996; 334: 1095-1099.
128. Oswald-Mammosser M, Kessler R, Massard G, Wihlm JM, Weitzenblum E, Lonsdorfer J. Effect of lung volume reduction surgery on gas exchange and pulmonary hemodynamics at rest and during exercise. Am J Respir Crit Care Med 1998; 158: 1020-1025.
129. Wagner PD. Functional consequences of lung volume reduction surgery for COPD. Am J Respir Crit Care Med 1998; 158: 1017-1019.
130. Newman JH. Treatment of primary pulmonary hypertension - the next generation. N Engl J Med 2002; 346: 933-935.
131. Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160: 600-607.
132. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900.